Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34531
Abstract: Patients with metastatic colorectal cancer (mCRC) have poor long-term survival. Rechallenge with anti-epidermal growth factor receptor (anti-EGFR) based therapy has shown certain activity as late-line therapy. To further improve clinical outcomes, we evaluated the antitumor… read more here.
Keywords: cetuximab; metastatic colorectal; liposomal irinotecan; camrelizumab liposomal ... See more keywords
Camrelizumab: an investigational agent for hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2022121
Abstract: INTRODUCTION : Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for advanced HCC. However, recent treatments with PD-1/PD-L1 inhibitor monotherapy and its combination with other therapies,… read more here.
Keywords: hepatocellular carcinoma; camrelizumab investigational; camrelizumab; investigational agent ... See more keywords
Comment on “Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma”
Sign Up to like & getrecommendations! Published in 2022 at "Contact Dermatitis"
DOI: 10.1111/cod.14179
Abstract: To the Editor, We read with great interest the article ‘Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma’ by Peng et al., presenting a case of a man who developed toxic epidermal… read more here.
Keywords: anti ssa; anti pd1; ssa antibody; camrelizumab ... See more keywords
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004656
Abstract: Objective This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. Methods Initially, 20 patients with HCC were screened and 18 patients… read more here.
Keywords: camrelizumab plus; therapy; plus apatinib; efficacy ... See more keywords
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0636-7
Abstract: Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking.… read more here.
Keywords: chemotherapy; safety; efficacy; camrelizumab ... See more keywords
Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-21-870
Abstract: Background To evaluate the cost-effectiveness of camrelizumab versus chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) from the perspective of health system and to provide a basis for health decisions in… read more here.
Keywords: analysis; cost effectiveness; chemotherapy; cost ... See more keywords
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
Sign Up to like & getrecommendations! Published in 2023 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-852
Abstract: Background Camrelizumab plus chemotherapy have been approved as standards for the treatment of advanced non-small cell lung cancer (NSCLC) patients based on two phase III trials. However, clinical trial results may not be representative of… read more here.
Keywords: lung cancer; safety; effectiveness safety; camrelizumab ... See more keywords
Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101)
Sign Up to like & getrecommendations! Published in 2023 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-23-121
Abstract: Background Camrelizumab has shown promising survival benefits in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients when used in combination with chemotherapy. However, its effectiveness and safety outside the clinical trial setting are largely unknown.… read more here.
Keywords: lung cancer; camrelizumab; safety; real world ... See more keywords
Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s335515
Abstract: Purpose The aim of this study was to assess the cost-effectiveness of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC), which was evaluated in the ESCORT… read more here.
Keywords: chemotherapy; camrelizumab; cost effectiveness; docetaxel irinotecan ... See more keywords
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
Sign Up to like & getrecommendations! Published in 2020 at "OncoTargets and therapy"
DOI: 10.2147/ott.s279004
Abstract: Abstract We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell… read more here.
Keywords: pulmonary pleomorphic; camrelizumab; partial response; pleomorphic carcinoma ... See more keywords
Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.784861
Abstract: HER2 amplification/overexpression is a common driver in a variety of cancers including gallbladder cancer (GBC). For patients with metastatic GBC, chemotherapy remains the standard of care with limited efficacy. The combination of HER2 antibody trastuzumab… read more here.
Keywords: cancer; chemotherapy; her2; antibody ... See more keywords